Back to List View Graph View

Angiotensin-converting enzyme 2 (ACE2)

Angiotensin I converting enzyme 2 (ACE2) is a membrane-associated protein best known as a key regulator of the renin–angiotensin system and as the cellular receptor used by SARS-CoV-2 for entry into host cells.

Where the papers sit

10 papers from the last 6 months study Angiotensin-converting enzyme 2 (ACE2) directly · updated from PubMed 12 Nov 2026

Study type 0 clinical trials · 2 observational · 6 human data · 2 preclinical

Themes 3 themes · 1 new direction

  • SARS-CoV-2 Entry Therapies

    ACE2-targeted antiviral design is moving from computational discovery toward engineered entry blockade and intracellular delivery. Candidate strategies include virtual screening, IL-27 gene therapy, and ACE2-PNA conjugates that use viral endocytosis. Nanoswitch screening and protein-lipid virus-like particles broaden the toolkit for finding or presenting antiviral agents. Efficacy remains exploratory, with SARS-CoV-2 entry and antiviral activity as recurring endpoints.

    5 papers · 50%

  • ACE2 in Cardiorenal Pregnancy

    ACE2 is being linked to cardiorenal and reproductive risk through circulating biomarkers and tissue-level regulation. In pregnancy, cardiovascular protein profiles are being evaluated for later preeclampsia and small-for-gestational-age outcomes. Kidney transplant work connects proteinuria with cardiac biomarker levels, while high-fat diet models implicate ACE2 downregulation in adverse cardiovascular and reproductive effects. The shared question is whether ACE2-related signals can improve risk stratification or explain disease mechanisms.

    3 papers · 30%

  • Antibody Escape in SARS-CoV-2

    Antibody escape mapping is shifting toward proactive prediction of SARS-CoV-2 variant resistance. Deep mutational scanning and machine learning are paired with iterative experiments to identify receptor-binding-domain changes that weaken antibody binding. The goal is to anticipate trajectories of emerging variants and preserve neutralization through antibody design or combination therapy. Wild-type comparisons remain important, but the durability of predictions across circulating variants is still open.

    2 papers · 20%

NEW DIRECTION

ACE2 is repurposed as a virus-triggered intracellular delivery conduit rather than only as a viral-entry receptor or extracellular neutralization target

The SARS-CoV-2 ACE2-PNA conjugate study used ACE2-Fc to carry peptide nucleic acids targeting the viral ORF1ab region into infected cells through virus-mediated endocytosis, while retaining ACE2’s extracellular neutralizing activity; thus, ACE2 becomes a receptor-drug conjugate that delivers an antiviral payload intracellularly, adding a delivery role not represented by the other studies’ receptor-blocking, interaction-modeling, protective-axis, or biomarker uses 42545604Aug.

Papers

The 10 papers from the last 6 months that study Angiotensin-converting enzyme 2 (ACE2) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

SARS-CoV-2 Entry Therapies (5)
  1. Discovering molecular modulators with nanoswitch screening. Science (New York, N.Y.) · 5 Nov 2026 PMID 42986965
  2. ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2. Molecular biomedicine · 3 Aug 2026 PMID 42545604
  3. Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry. Molecular biology reports · 11 Jul 2026 PMID 42435246
  4. Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction. ChemMedChem · 22 May 2026 PMID 42174382
  5. Bottom-Up Creation of Virus-like Particles via Post-Insertion of Protein-Lipid Conjugates. ACS synthetic biology · 20 May 2026 PMID 42160665
ACE2 in Cardiorenal Pregnancy (3)
  1. Correlation between proteinuria and cardiac biomarker levels in kidney transplant recipients. Renal failure · 10 Nov 2026 PMID 43009172
  2. ACE2 downregulation contributes to adverse cardiovascular and reproductive outcomes in female mice on high-fat diet. American journal of physiology. Heart and circulatory physiology · 8 Sept 2026 PMID 42710476
  3. A case-control study of mid-pregnancy circulating cardiovascular proteins in women with subsequent preeclampsia and small for gestational age births. Scientific reports · 6 Jul 2026 PMID 42409921
Antibody Escape in SARS-CoV-2 (2)
  1. Evaluating SARS-CoV-2 antibody resilience via prediction and design of escape viral variants. Cell systems · 17 Jul 2026 PMID 42468530
  2. Combining machine learning and iterative experiments to keep pace with emerging viral variants of concern. PLoS computational biology · 17 Jun 2026 PMID 42308256

By study type

Observational studies and case reports (2)
  1. Correlation between proteinuria and cardiac biomarker levels in kidney transplant recipients. Renal failure · 10 Nov 2026 PMID 43009172
  2. A case-control study of mid-pregnancy circulating cardiovascular proteins in women with subsequent preeclampsia and small for gestational age births. Scientific reports · 6 Jul 2026 PMID 42409921
Human data, design not indexed (6)
  1. Discovering molecular modulators with nanoswitch screening. Science (New York, N.Y.) · 5 Nov 2026 PMID 42986965
  2. Evaluating SARS-CoV-2 antibody resilience via prediction and design of escape viral variants. Cell systems · 17 Jul 2026 PMID 42468530
  3. Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry. Molecular biology reports · 11 Jul 2026 PMID 42435246
  4. Combining machine learning and iterative experiments to keep pace with emerging viral variants of concern. PLoS computational biology · 17 Jun 2026 PMID 42308256
  5. Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction. ChemMedChem · 22 May 2026 PMID 42174382
  6. Bottom-Up Creation of Virus-like Particles via Post-Insertion of Protein-Lipid Conjugates. ACS synthetic biology · 20 May 2026 PMID 42160665
Preclinical: animal, cell and lab studies (2)
  1. ACE2 downregulation contributes to adverse cardiovascular and reproductive outcomes in female mice on high-fat diet. American journal of physiology. Heart and circulatory physiology · 8 Sept 2026 PMID 42710476
  2. ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2. Molecular biomedicine · 3 Aug 2026 PMID 42545604